Prostate Biopsy Articles & Analysis
13 articles found
The literature shows that pathologists, being only humans under considerable pressure, may miss cancer in up to 1-3% of prostate biopsies.2,3,4 Considering the over one million men who are diagnosed worldwide per year, this may reflect a large number of patients.5 Moreover, the subjectivity of Gleason grading and tumor quantification can result in difficulty ...
Yale Medicine, an academic medical center with a high volume of prostate biopsies, conducted a study to determine Paige Prostate’s utility as a prescreening tool for clinical use. A total of 1,876 prostate core biopsy slides were analyzed by Paige Prostate, and only those cores categorized ...
The ClarityDX Prostate® test uses a proprietary machine-learning algorithm that combines data from biological and clinical biomarkers to generate a risk score for clinically significant prostate cancer, defined as Gleason grade group 2 or higher, on prostate biopsy. The ClarityDX Prostate® test is ...
Using ClarityDX Prostate® as a reflex test vs. PSA test alone could have resulted in 37% fewer unnecessary biopsies. ...
We evaluated SelectMDx clinical performance in a cohort of German men undergoing initial prostate biopsy.Methods:The study population consisted of 443 men sequentially enrolled men who underwent initial prostate biopsy between July 2009 and December 2014 due to suspected PCa. Post-DRE urine was collected from all subjects prior to ...
Compared to transrectal, transperineal is proven to be the cleaner and ultimately safer approach for prostate biopsies. The support for transperineal is growing, as mounting evidence continues to debunk previous misconceptions of tolerability, feasibility and accuracy. ...
Summary Nanostics' clinical validation study for ClarityDX Prostate, a liquid biopsy test for the early diagnosis of clinically significant prostate cancer, re-opens recruitment after lifting of COVID-19 research restrictions A top-ranked research institute in the Northeast US will now partner with Nanostics' by recruiting patients for the ...
EDAP’s position as a leader in the urology market, its HIFU technology, and its track record of innovation in providing minimally invasive therapy solutions to prostate cancer patients provide an excellent complement to Exact Imaging’s technology. ...
Summary This study is designed to determine the accuracy of the blood test ClarityDX Prostate to predict the results of prostate biopsies in men who have PSA (Prostate Specific Antigen) greater than 3 and no higher than 10 ...
The Yukon chapter of Ride For Dad says a new blood test developed by an Alberta-based company could save the lives of men at risk of prostate cancer. (iStock/Getty Images) A bio-technology company based in Alberta is testing a new process that could result in fewer Yukon men travelling out of territory for prostate cancer biopsies. Private ...
Abstract Objective: To evaluate an epigenetic assay performed on tissue from negative prostate biopsies in a group of African American (AA) men undergoing repeat biopsy, and to compare accuracy for predicting repeat biopsy outcome to prior studies conducted in predominantly Caucasian populations. Materials and methods: ...
Materials and methods: We developed a Markov decision analytical model to simulate the chain of events and downstream outcomes associated with ultrasound guided prostate biopsy and a strategy in which the biomarker panel is implemented prior to biopsy. ...
Abstract Background: Prostate cancer (PCa) diagnosis is challenging because efforts for effective, timely treatment of men with significant cancer typically result in over-diagnosis and repeat biopsies. ...